Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback